JOURNAL ARTICLE
RESEARCH SUPPORT, N.I.H., EXTRAMURAL
RESEARCH SUPPORT, NON-U.S. GOV'T
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

Timing of preoperative antibiotic prophylaxis: a modifiable risk factor for deep surgical site infections after pediatric spinal fusion.

BACKGROUND: Deep surgical site infections (SSI) after spinal fusion are healthcare-associated infections that result in increased morbidity, hospital stay, and health care costs. Risk factors for these infections among children are poorly characterized.

METHODS: We performed a case-control study nested within a cohort of all children, from birth to 18 years of age, who underwent spinal fusion at Johns Hopkins Hospital between July 1, 2000 and June 30, 2006.

RESULTS: Thirty-six deep SSI were identified. The incidence of deep SSI was 3.4%. Infection was diagnosed a median of 15 days after surgery (interquartile range, 9-28). Significant risk factors for deep SSI included inappropriate timing of preoperative antibiotic prophylaxis, previous spine surgery, presence of a complex underlying medical condition, age, >10 vertebrae fused, and an increased estimated blood loss per kilogram body weight. After controlling for previous spine surgery, number of vertebrae fused, and complex underlying medical condition, inappropriate timing of preoperative antibiotic prophylaxis administration was a significant independent risk factor for deep SSI (odds ratio: 3.5; 95% confidence interval: 1.7-7.3; P = 0.001).

DISCUSSION: Timing of preoperative antibiotic prophylaxis is an independent and modifiable risk factor for deep SSI after pediatric spinal fusion. Our findings suggest that all pediatric patients undergoing pediatric spinal fusion should have preoperative antibiotic prophylaxis given within 60 minutes before incision to reduce the risk of SSI and the morbidity and costs associated with hardware removal and repeat spinal fusion.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app